• 1
    Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008; 359:391403.
  • 2
    Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276:6316.
  • 3
    Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998; 83:34806.
  • 4
    Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88:421420.
  • 5
    Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008; 93:338995.
  • 6
    Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010; 95:26808.
  • 7
    Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010; 21:192734.
  • 8
    Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26:235870.
  • 9
    Chu NN, Li XN, Chen WL, Xu HR. Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers. Pharmazie. 2007; 62:86971.
  • 10
    Fox J, Wells DS, Garceau RJ. Relationships between pharmacokinetic profile of human PTH(1-84) and serum calcium response in postmenopausal women following four different methods of administration. J Bone Miner Res [Internet]. 2011; [cited 2013 Apr 28]; 26(Suppl 1). Available from:
  • 11
    Li Q, Qiao J, Deng J, Zeng T, Zhou P, Li W. Safety, tolerability and pharmacokinetic study of recombinant human parathyroid hormone [rhPTH (1-84)] in Chinese healthy volunteers. J Huazhong Univ Sci Technolog Med Sci. 2009; 29:4314.
  • 12
    Schwietert HR, Groen EW, Sollie FA, Jonkman JH. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther. 1997; 61:36076.
  • 13
    Laursen T, Jorgensen JO, Christiansen JS. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clin Endocrinol (Oxf). 1994; 40:3738.
  • 14
    Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984; 7:18899.
  • 15
    Maunsell Z, Wright DJ, Rainbow SJ. Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin Chem. 2005; 51:168390.
  • 16
    Hojskov CS, Heickendorff L, Moller HJ. High-throughput liquid-liquid extraction and LCMSMS assay for determination of circulating 25(OH) vitamin D3 and D2 in the routine clinical laboratory. Clinica Chimica Acta. 2010; 411:1146.
  • 17
    FDA, ICH 2011 Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2011. p.116. Avaliable at the FDA website at:
  • 18
    Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012; 97:3919.
  • 19
    Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000; 89:297310.
  • 20
    McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol. 2005; 2:8996.
  • 21
    Porter CJ, Edwards GA, Charman SA. Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev. 2001; 50:15771.
  • 22
    Bikle D, Adams J, Christakos S. Chapter 28. Vitamin D: production, metabolism, mechanism of action, and clinical requirements. In: Rosen CJ, Compston JE, Lian JB, editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. Hoboken, NJ: John Wiley & Sons, Inc, 2008. p.1419.
  • 23
    Armbrecht HJ, Boltz MA, Hodam TL. PTH increases renal 25(OH)D3-1alpha -hydroxylase (CYP1alpha) mRNA but not renal 125(OH)2D3 production in adult rats. Am J Physiol Renal Physiol. 2003; 284:F10326.
  • 24
    Bogin E, Harary I. The relationship of calcium and parathyroid hormone in their effect on heart cells. Mol Cell Biochem. 1987; 77:2935.
  • 25
    Rampe D, Lacerda AE, Dage RC, Brown AM. Parathyroid hormone: an endogenous modulator of cardiac calcium channels. Am J Physiol. 1991; 261:H194550.
  • 26
    Wang R, Wu LY, Karpinski E, Pang PK. The effects of parathyroid hormone on L-type voltage-dependent calcium channel currents in vascular smooth muscle cells and ventricular myocytes are mediated by a cyclic AMP dependent mechanism. FEBS Lett. 1991; 282:3314.
  • 27
    Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest. 1981; 67:121527.
  • 28
    Fryer RM, Segreti JA, Widomski DL, Franklin PH, Banfor PN, Koch KA, Nakane M, Wu-Wong JR, Cox BF, Reinhart GA. Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet. J Pharmacol Exp Ther. 2007; 323:21726.
  • 29
    Wolzt M, Schmetterer L, Dorner G, Zelger G, Entlicher J, Kapiotis S, Eichler HG. Hemodynamic effects of parathyroid hormone-related peptide-(1-34) in humans. J Clin Endocrinol Metab. 1997; 82:254851.
  • 30
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349:120715.
  • 31
    Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis. J Clin Densitom. 2011; 14:6873.
  • 32
    Moricke R, Rettig K, Bethke TD. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain - the PROPOSE study. Clin Drug Investig. 2011; 31:8799.
  • 33
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007; 146:32639.
  • 34
    Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94:3359.